Submit Your Privacy Request
*Required field.
Do Not Sell My Data
Mirum Pharmaceuticals, Inc. complies with the California Consumer Privacy Act (“CCPA”), which gives California residents the right to opt out of the “sale” of their personal information that we collect from their use of our site.
Mirum does not sell your personal information for money to anyone. However, the definition of “sale” under the CCPA is very broad and therefore may include certain types of sharing.
If you have questions regarding this form or have difficulty accessing it, please contact us at privacy@mirumpharma.com.
Please note: a separate form will need to be submitted for each request.
Thank you for submitting your request!
YIKES!
We're having some connection trouble.
Please refresh the page and try submitting your form again. If the issue persists, please contact us.
INDICATIONS
LIVMARLI is a prescription medicine used to treat:
- cholestatic pruritus (itch) in patients who are 3 months of age and older with Alagille syndrome
- cholestatic pruritus (itch) in patients who are 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
- LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein
It is not known if LIVMARLI is safe and effective in children with Alagille syndrome who are under 3 months of age. It is not known if LIVMARLI is safe and effective in children with PFIC who are under 12 months of age. It is not known if LIVMARLI is safe and effective in adults who are 65 years of age and older.
IMPORTANT SAFETY INFORMATION
What are the possible side effects
of LIVMARLI?
- Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but may worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to transplant or death. Your health care provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:
- nausea or vomiting
- your skin or the white part of your eye turns yellow
- dark or brown urine
- pain on the right side of your stomach (abdomen)
- fullness, bloating, or fluid in your stomach area (ascites)
- loss of appetite
- bleeding or bruising more easily than normal, including vomiting blood
- Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Diarrhea can also cause the loss of too much body fluid (severe dehydration). Your health care provider may advise you to monitor for new or worsening stomach problems, including stomach pain, diarrhea, blood in your stool, or vomiting
Tell your health care provider right away if you have any new or worsening signs or symptoms of stomach and intestinal problems, including:- diarrhea
- more frequent bowel movements than usual
- stools that are black, tarry, or sticky, or have blood or mucous
- severe stomach-area pain or tenderness
- vomiting
- urinating less often than usual
- dizziness
- headache
- A condition called Fat-Soluble Vitamin (FSV) Deficiency, caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat, is common in patients with Alagille syndrome and PFIC, but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment, and may monitor for bone fractures and bleeding, which are common side effects
Tell your health care provider about all medicines that you take, as LIVMARLI may interact with other medicines. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.
Your health care provider may change your dose, or temporarily or permanently stop treatment if you have certain side effects.
In patients with Alagille syndrome, LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. In patients with PFIC, LIVMARLI is taken by mouth, 2 times each day, 30 minutes before a meal. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.
These are not all of the possible side effects of LIVMARLI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
